OBJECTIVE: Some molecular and histological evidence suggests that mucinous epithelial ovarian cancers develop via a sequence from benign tumor through borderline tumor to invasive cancer. Such a sequence would predict some shared risk factors between the different tumor types. To investigate this, we examined risk factors for benign, borderline and invasive mucinous ovarian tumors. METHODS: A population-based case-control study was conducted in Australia between 2002 and 2005. Women with benign (n=133), borderline (n=147) and invasive (n=43) mucinous tumors of the ovary and women from the general population (n=1487) completed comprehensive health and lifestyle questionnaires. RESULTS: Although parity was inversely related to risk of benign, borderline and invasive tumors, increasing numbers of births did not further decrease risk of any of the tumor types. Hormonal contraceptives and breast-feeding were unrelated to risk. However, 20 or more pack-years of smoking was associated with a more than twofold increase in risk of all three tumor types (OR=2.7, 95% CI 1.6-4.4 for benign tumors; OR=2.7, 95% CI 1.7-4.4 for borderline tumors; and OR=2.1, 95% CI 0.9-5.0 for invasive cancers) compared to never smoking. CONCLUSIONS: Overall, the risk factors for mucinous cancers appear to differ from other subtypes of ovarian cancer. Furthermore, patterns of risk factors across benign, borderline and invasive mucinous ovarian tumors are generally consistent with an adenoma-to-carcinoma sequence as the developmental pathway for this subtype of ovarian cancer. Our findings also suggest the potential preventability of borderline and invasive mucinous ovarian cancer by smoking cessation and by surgical excision of identifiable precursor lesions.
OBJECTIVE: Some molecular and histological evidence suggests that mucinous epithelial ovarian cancers develop via a sequence from benign tumor through borderline tumor to invasive cancer. Such a sequence would predict some shared risk factors between the different tumor types. To investigate this, we examined risk factors for benign, borderline and invasive mucinous ovarian tumors. METHODS: A population-based case-control study was conducted in Australia between 2002 and 2005. Women with benign (n=133), borderline (n=147) and invasive (n=43) mucinous tumors of the ovary and women from the general population (n=1487) completed comprehensive health and lifestyle questionnaires. RESULTS: Although parity was inversely related to risk of benign, borderline and invasive tumors, increasing numbers of births did not further decrease risk of any of the tumor types. Hormonal contraceptives and breast-feeding were unrelated to risk. However, 20 or more pack-years of smoking was associated with a more than twofold increase in risk of all three tumor types (OR=2.7, 95% CI 1.6-4.4 for benign tumors; OR=2.7, 95% CI 1.7-4.4 for borderline tumors; and OR=2.1, 95% CI 0.9-5.0 for invasive cancers) compared to never smoking. CONCLUSIONS: Overall, the risk factors for mucinous cancers appear to differ from other subtypes of ovarian cancer. Furthermore, patterns of risk factors across benign, borderline and invasive mucinous ovarian tumors are generally consistent with an adenoma-to-carcinoma sequence as the developmental pathway for this subtype of ovarian cancer. Our findings also suggest the potential preventability of borderline and invasive mucinous ovarian cancer by smoking cessation and by surgical excision of identifiable precursor lesions.
Authors: Kevin M Elias; S Intidhar Labidi-Galy; Allison F Vitonis; Jason L Hornick; Leona A Doyle; Michelle S Hirsch; Daniel W Cramer; Ronny Drapkin Journal: Gynecol Oncol Date: 2013-12-14 Impact factor: 5.482
Authors: Suzanne C Dixon-Suen; Penelope M Webb; Louise F Wilson; Karen Tuesley; Louise M Stewart; Susan J Jordan Journal: J Natl Cancer Inst Date: 2019-10-01 Impact factor: 13.506
Authors: Lilah Khoja; Rachel Palmieri Weber; Penelope M Webb; Susan J Jordan; Aruna Muthukumar; Jenny Chang-Claude; Renée T Fortner; Allan Jensen; Susanne K Kjaer; Harvey Risch; Jennifer Anne Doherty; Holly R Harris; Marc T Goodman; Francesmary Modugno; Kirsten Moysich; Andrew Berchuck; Joellen M Schildkraut; Daniel Cramer; Kathryn L Terry; Hoda Anton-Culver; Argyrios Ziogas; Minh Tung Phung; Gillian E Hanley; Anna H Wu; Bhramar Mukherjee; Karen McLean; Kathleen Cho; Malcolm C Pike; Celeste Leigh Pearce; Alice W Lee Journal: Gynecol Oncol Date: 2021-11-12 Impact factor: 5.304
Authors: Jennifer A Doherty; Mary Anne Rossing; Kara L Cushing-Haugen; Chu Chen; David J Van Den Berg; Anna H Wu; Malcolm C Pike; Roberta B Ness; Kirsten Moysich; Georgia Chenevix-Trench; Jonathan Beesley; Penelope M Webb; Jenny Chang-Claude; Shan Wang-Gohrke; Marc T Goodman; Galina Lurie; Pamela J Thompson; Michael E Carney; Estrid Hogdall; Susanne Kruger Kjaer; Claus Hogdall; Ellen L Goode; Julie M Cunningham; Brooke L Fridley; Robert A Vierkant; Andrew Berchuck; Patricia G Moorman; Joellen M Schildkraut; Rachel T Palmieri; Daniel W Cramer; Kathryn L Terry; Hannah P Yang; Montserrat Garcia-Closas; Stephen Chanock; Jolanta Lissowska; Honglin Song; Paul D P Pharoah; Mitul Shah; Barbara Perkins; Valerie McGuire; Alice S Whittemore; Richard A Di Cioccio; Aleksandra Gentry-Maharaj; Usha Menon; Simon A Gayther; Susan J Ramus; Argyrios Ziogas; Wendy Brewster; Hoda Anton-Culver; Celeste Leigh Pearce Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01 Impact factor: 4.254
Authors: Mary Anne Rossing; Kara L Cushing-Haugen; Kristine G Wicklund; Jennifer A Doherty; Noel S Weiss Journal: Cancer Causes Control Date: 2008-08-14 Impact factor: 2.506
Authors: Mette T Faber; Susanne K Kjær; Christian Dehlendorff; Jenny Chang-Claude; Klaus K Andersen; Estrid Høgdall; Penelope M Webb; Susan J Jordan; Mary Anne Rossing; Jennifer A Doherty; Galina Lurie; Pamela J Thompson; Michael E Carney; Marc T Goodman; Roberta B Ness; Francesmary Modugno; Robert P Edwards; Clareann H Bunker; Ellen L Goode; Brooke L Fridley; Robert A Vierkant; Melissa C Larson; Joellen Schildkraut; Daniel W Cramer; Kathryn L Terry; Allison F Vitonis; Elisa V Bandera; Sara H Olson; Melony King; Urmila Chandran; Lambertus A Kiemeney; Leon F A G Massuger; Anne M van Altena; Sita H Vermeulen; Louise Brinton; Nicolas Wentzensen; Jolanta Lissowska; Hannah P Yang; Kirsten B Moysich; Kunle Odunsi; Karin Kasza; Oluwatosin Odunsi-Akanji; Honglin Song; Paul Pharaoh; Mitul Shah; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Rebecca Sutphen; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Celeste Leigh Pearce; Anna H Wu; Malcolm C Pike; Harvey A Risch; Allan Jensen Journal: Cancer Causes Control Date: 2013-03-02 Impact factor: 2.506
Authors: Ana Babic; Naoko Sasamoto; Bernard A Rosner; Shelley S Tworoger; Susan J Jordan; Harvey A Risch; Holly R Harris; Mary Anne Rossing; Jennifer A Doherty; Renée T Fortner; Jenny Chang-Claude; Marc T Goodman; Pamela J Thompson; Kirsten B Moysich; Roberta B Ness; Susanne K Kjaer; Allan Jensen; Joellen M Schildkraut; Linda J Titus; Daniel W Cramer; Elisa V Bandera; Bo Qin; Weiva Sieh; Valerie McGuire; Rebecca Sutphen; Celeste L Pearce; Anna H Wu; Malcolm Pike; Penelope M Webb; Francesmary Modugno; Kathryn L Terry Journal: JAMA Oncol Date: 2020-06-11 Impact factor: 33.006